---
schema_version: "secwatch.filing_event.v1"
accession: "0001757073-25-000042"
form_type: "8-K"
ticker: "NVST"
cik: "0001757073"
company_name: "Envista Holdings Corp"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:23:58.553297+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15

## Summary
- Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).
- Core sales growth 5.6% YoY across all businesses and geographies, including Nobel Biocare in North America.
- FY2025 guidance raised: core sales growth 3-4% (prior 1-3%), adjusted EPS $1.05-$1.15 (prior $0.95-$1.05).
- Repurchased 4.8M shares for ~$82M in Q2; $150M remaining under buyback program.
- YTD operating cash flow $89M, free cash flow $71M, down from $133M and $116M in H1 2024.

## SEC filing metadata
- accession: 0001757073-25-000042
- form_type: 8-K
- ticker: NVST
- cik: 0001757073
- company_name: Envista Holdings Corp
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757073/000175707325000042/0001757073-25-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757073/000175707325000042/nvst-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001757073-25-000042
- JSON: https://secwatch.observer/filing/0001757073-25-000042.json
- Plain text: https://secwatch.observer/filing/0001757073-25-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.